Non-Peptidic Cell-Penetrating Motifs for Mitochondrial Cargo Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing therapeutic agents, such as peptides and nucleic acids, face challenges in penetrating the mitochondrial membrane due to their lack of membrane-permeability, complicating the delivery of cargo to the mitochondrial matrix for treating mitochondrial-related diseases.
Innovation Solution
Development of non-peptidic cell-penetrating motifs (CPMs) with specific structures, including multivalent moieties and hydrophobic residues, to facilitate the transport of therapeutic agents across mitochondrial membranes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If peptides and nucleic acids are used as therapeutic agents, then they can provide specific therapeutic effects, but they cannot penetrate the mitochondrial membrane due to lack of membrane-permeability
Solution Approach 1:
The patent introduces cell-penetrating motifs (CPMs) as intermediary structures that facilitate the transport of therapeutic agents (peptides and nucleic acids) across the mitochondrial membrane. These CPMs act as mediators between the hydrophilic therapeutic cargo and the hydrophobic membrane barrier, enabling permeation through interactions with both phases. The CPMs are designed with specific structural features including positively charged groups and hydrophobic regions that allow them to traverse the membrane and deliver cargo to the mitochondrial matrix.
Solution Approach 2:
The patent employs composite molecular structures combining multiple functional elements: hydrophilic therapeutic agents (peptides or nucleic acids), amphipathic cell-penetrating motifs with both hydrophilic and hydrophobic regions, and lipid-like components. This composite architecture allows the therapeutic complex to simultaneously interact with the aqueous cytosolic environment and the lipophilic membrane, overcoming the permeability barrier while maintaining therapeutic specificity.
2Ease of operation
If conventional therapeutic agents are used, then they can be easily administered, but they fail to reach the mitochondrial matrix for effective treatment
Solution Approach 1:
The patent divides the delivery system into distinct functional segments: (1) the therapeutic cargo (peptide or nucleic acid) that provides the therapeutic effect, (2) the cell-penetrating motif that facilitates membrane crossing, and (3) the mitochondrial targeting elements that ensure delivery to the correct compartment. This segmentation allows each component to be optimized independently - the cargo for therapeutic activity, the CPM for membrane permeability, and the targeting elements for mitochondrial localization - while maintaining overall system functionality.
Solution Approach 2:
The cell-penetrating motifs are designed with spatially differentiated functional regions: hydrophilic segments for interaction with aqueous environments and cytosolic cargo, hydrophobic segments for interaction with the lipid membrane, and positively charged groups for membrane penetration. This local quality differentiation within the CPM structure enables it to perform multiple functions at different locations, facilitating efficient delivery to the mitochondrial matrix while maintaining ease of administration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The CPMs effectively deliver cargo to mitochondria, demonstrating high cytosolic entry efficiency and mitochondrial localization, thereby providing a potential therapeutic approach for mitochondrial diseases.
Implementation Method 1
each R1 is independently a moiety comprising a hydrophobic residue
Implementation Method 2
facilitate the transport of therapeutic agents across mitochondrial membranes
Data Source
AI summary
Disclosed are compounds that can penetrate the mitochondrial membrane and that are able to deliver cargo (e.g., therapeutic agents) specifically to the mitochondria.